4D Molecular Therapeutics, Inc. (FDMT) vs Solid Biosciences Inc. (SLDB)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Solid Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SLDB
Solid Biosciences Inc.
$6.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FDMT vs SLDB
growth of $100 · dividends reinvested · last 6yFDMT -68.1% (-17.3%/yr)SLDB -87.0% (-28.9%/yr)FDMT compounded faster over this window
FDMT SLDB
FDMT vs SLDB: by the numbers
- •SLDB is the larger company ($681M vs $657M market cap).
- •Both run net losses; SLDB's is the smaller (0.00% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | FDMT | SLDB |
|---|---|---|
| P/S ratio | 7.14 | N/A |
| P/B ratio | 1.61 | 1.82 |
Profitability
| Metric | FDMT | SLDB |
|---|---|---|
| Gross margin | 91.05% | 0.00% |
| Operating margin | -187.24% | 0.00% |
| Net margin | -194.74% | 0.00% |
| ROE | -43.95% | -55.36% |
| ROIC | -44.30% | -54.12% |
Growth (annualized)
| Metric | FDMT | SLDB |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | N/A |
| Total return CAGR (5Y) | -13.08% | -27.50% |
Frequently asked
- How have FDMT and SLDB total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and SLDB delivered -27.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROESolid Biosciences ROE4D Molecular Therapeutics operating marginSolid Biosciences operating margin4D Molecular Therapeutics revenue growthSolid Biosciences revenue growth4D Molecular Therapeutics free cash flowSolid Biosciences free cash flow
4D Molecular Therapeutics & Solid Biosciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.